Mariusz Kuśmierczyk, Jacek Różański, Michał Zembala, Dariusz Dudek, Wojciech Braksator, Tomasz Grodzicki, Piotr Hoffman, Jerzy Sadowski, Marcin Gruchała, Jacek Legutko, Piotr Siondalski, Karol Wierzbicki, Bogusław Kapelak, Grzegorz Opolski, Andrzej Juraszek, Katarzyna Bondaryk, Jacek Walczak, Izabela Pieniążek, Maciej Grys, Piotr Przygodzki
Patients with severe heart failure (HF), who are not eligible for cardiac transplantation and receive optimal medical management, based mainly on the use of pharmacological treatment and devices such as resynchronization therapy (implantable cardioverter-defibrillator), achieve poor clinical outcomes and constitute a group with extremely poor prognosis. Currently, the technology used in the latest generation left ventricular assist devices (LVADs), such as the HeartMate3, makes it possible to achieve patient survival at the level obtained by patients after heart transplantation, and they can be used not only in patients eligible for heart transplantation as a bridge to transplant, but also in those with significantly worse prognosis, who are ineligible for heart transplantation as destination therapy...
November 3, 2020: Cardiology Journal